70 results about "Naloxazone" patented technology

Devices for intranasal administration of naloxone are disclosed. The devices comprise a foam applicator and are configured to locate an applicator comprising a naloxone composition, in proximity to the middle turbinate and / or inferior turbinate. Naloxone can be delivered to the nasal mucosa by squeezing the nostril against the applicator. The device and methods of using the devices can be used to treat an opioid overdose.

A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery. This system offers precision and adaptability in treating conditions related to opioid overdose, dependency, and xylazine exposure.

The present invention describes an immediate release oral solid pharmaceutical formulation consisting of all water-soluble components and comprising methadone (Met) or levomethadone (Lev) and optionally naloxone in weight ratio Met / Nal 40-60:1 or Lev / Nal 20-30:1; the solid formulation being critical excipients free and totally dissolving in water. The solid oral formulation of the invention in presence of naloxone is effective equally as methadone / levomethdone alone in the maintenance treatment of opioid addicts and is diversion and misuse deterrent by virtue of the presence of naloxone.

Aspects of the invention include topical naloxone compositions for locally delivering naloxone to the skin of a subject. Topical compositions according to certain embodiments are storage stable non-aqueous topical compositions that include naloxone free base and a non-aqueous vehicle, wherein the compositions are substantially free of naloxone N-oxide. Also provided are methods of using the topical compositions to locally deliver naloxone to a subject, as well as kits containing the topical naloxone compositions.

Disclosed herein are methods useful for the synthesis of benzylisoquinoline alkaloids ("BIA"), such as alkaloid morphinans. The disclosed methods can be used to produce thebaine, eastern papaverine, codeine, morphine, oxycodone, hydrocodone, oxymorphinone, hydromorphinone, naltrexone, naloxone, hydroxycodeinone, neolpinone, and / or buprenorphine.

Described herein is a crystalline naloxone-dimethylformamide solvate and methods of making a first and a second amount thereof, as well as methods of making naloxone or a naloxone salt, involving said crystalline naloxone-dimethylformamide solvate. Further described herein is the use of dimethylformamide for preparing said crystalline naloxone-dimethylformamide solvate and the use of said crystalline naloxone-dimethylformamide solvate as a reagent for i.a. purifying naloxone. Moreover, it is described a crystalline naloxone, a use thereof and a method of making it, as well as a mixture comprising dimethylformamide and said crystalline naloxone-dimethylformamide solvate.

Provided are formulations and methods to treat ultra-potent synthetic opioid overdose with high dose Naloxone formulations comprising naloxone hydrochloride or a pharmaceutically acceptable salt thereof, one or more preservatives, one or more buffering agents, a tonicity modifier, and optionally a pH modifier.

The present disclosure provides a naloxone film product for treatment and prevention of opioid overdoses. Also provided is a method of making the film product. The film product comprises a naloxone composition and at least one polymer.

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

Naloxone variants that are both long lasting and responsive are disclosed. One version of the compound has a boron ester functional group and the antagonist compound is capable of a sustained release of antagonist based on reaction with hydrogen peroxide. In addition, a method of treating opioid overdose is disclosed. The method involves administering a therapeutically effective amount of the formulation described above to a patient in need thereof. Administration occurs either intranasally, sublingually or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly.

The invention presented is a remedial opioid overdose mixture that includes a therapeutically effective dose of an opioid receptor antagonist; and, a therapeutically effective dose of an opioid receptor agonist. In one embodiment, the opioid receptor antagonist is naloxone while the opioid receptor agonist is nalbuphine. One specific naloxone derivative is NX-90 and a specific nalbuphine derivative is NB-33. The mixture can be administered intranasally, intravenously and by autoinjector. In some dose mixtures, reversal time is about three minutes.

The Overdose Reviver Pressurized Spray, provides two different methods to administer Narcan solution intranasally, containing enough Narcan solution, and pressurized air for at least ten one second 4 mg squirts of Narcan solution with or without a 3″ long extension air tube. To aim from the base of a nostril, depress an atomizing air release valve, administering atomized, pressurized Narcan solution into the nostrils of an unconscious, opioid overdosed person. Or to remove an air release valve, insert a pressurized air canister with Narcan solution into The Overdose Reviver Automatic Inhaler, supplying the necessary pressurized air, and Narcan solution for an Automatic Inhaler to perform its automatic reviving method. Wherein a microprocessor chip detects a life-threatening low heart rate, an Automatic Inhaler will automatically, repeatedly, administer atomized, pressurized Narcan solution into the nostrils of an unconscious opioid overdosed person once every two to three minutes and alert for help.

Aspects of the invention include topical naloxone compositions for locally delivering naloxone to the skin of a subject. Topical compositions according to certain embodiments are storage stable non-aqueous topical compositions that include naloxone free base and a non-aqueous vehicle, wherein the compositions are substantially free of naloxone N-oxide. Also provided are methods of using the topical compositions to locally deliver naloxone to a subject, as well as kits containing the topical naloxone compositions.

Mu opioid receptor (MOR) antagonists that specifically and effectively reverse the acute and chronic toxicity of fentanyl and its analogs are provided. The antagonists were developed by modifying the structural skeleton of fentanyl and / or phenylfentanil. The antagonists compete with fentanyls at the MOR binding site and when bound, they reverse the toxicity of fentanyls more effectively and selectively or specifically than naloxone, naltrexone, and other epoxymorphinan-type opioids.

A recombinant microbial host cell having improved in vivo conversion of reticuline and derivatives thereof (such as thebaine and / or oripavine) to relevant downstream opioids (such as neopinone, oripavine, northebaine, nororipavine or morphinone) and related compounds (such as heroin, morphine, codeine, thebaine, oripavine, oxycodone, hydrocodone, hydromorphone, oxymorphone, buprenorphine, naltrexone, naloxone or nalbuphine), wherein the microbial (such as fungal) host cell is heterologously expressing at least one functional transporter protein capable of transporting reticuline or a derivative thereof (such as thebaine and / or oripavine) and a heterologously expressed enzyme capable of acting upon reticuline or a derivative thereof. The invention also relates to uses of the microbial host cells and methods of making an opioid compound and / or opioid precursor compound and / or opioid derivative of interest.

The invention provides naloxone-loaded adhesive hydrogel as well as a preparation method and application thereof, and relates to the technical field of adhesive hydrogel. The naloxone-carrying adhesive hydrogel is obtained by cross-linking boric acid oxidized chondroitin sulfate and methacrylated gelatin; and naloxone and hectorite nano particles are loaded in the naloxone carrying adhesive hydrogel. The naloxone-loaded hydrogel constructed by the invention is used for repairing damage of bone and nervous tissues, naloxone is used as a small molecule drug, has more stable physical and chemical properties, is easier to store, and also has the functions of promoting osteogenesis and neurogenesis, so that the combined use of various bioactive factors is reduced; and the naloxone-carrying adhesive hydrogel has adhesive performance, can effectively fill a bone defect area and form a stable repair microenvironment, and accelerates the bone and nervous tissue regeneration efficiency.

Disclosed are antibodies that specifically bind to naloxone or naltrexone. Conjugates for producing the antibodies, and methods of producing the antibodies, are also disclosed. Also disclosed are methods of using the antibodies in direct assays of naloxone or naltrexone. Further disclosed are methods of using the antibodies to reduce naloxone or naltrexone interference in opiate assays.

Aspects of the present invention include topical naloxone compositions for the local delivery of naloxone to the skin of a subject. The topical compositions according to certain embodiments are storage-stable, non-aqueous topical compositions comprising a free naloxone base and a non-aqueous solvent, wherein said compositions are substantially free of naloxone N-oxide. The present invention also provides methods for using said topical compositions to locally deliver naloxone to a subject, and kits containing said topical naloxone compositions.

A method of producing promorphinan, morphinan, nal-opioid, and nor-opioid alkaloid products through the increased conversion of a promorphinan alkaloid to a morphinan alkaloid. The method comprises contacting the promorphinan alkaloid with at least one enzyme. Contacting the promorphinan alkaloid with the at least one enzyme converts the promorphinan alkaloid to a morphinan alkaloid.

Described herein are compositions, devices, and methods useful for treating (reversing) and / or preventing fentanyl overdose resulting in respiratory failure or airway obstruction (FIVCC). Compositions are provided that include optimized amounts and / or ratios of two active ingredients, including: an alpha 2 adrenergic receptor agonist (e.g., lofexidine, dexmedetomidine, clonidine) and a short acting mu opioid receptor antagonist (e.g., naloxone); an alpha 2 adrenergic receptor agonist and a long acting mu opioid receptor antagonist (nalmefene); and an alpha 2 adrenergic receptor agonist and a fentanyl opioid analgesic. Methods and devices for concurrent delivery of combined active ingredients are also provided.

To provide an agent that increases the expression of BAD, for use in the treatment of cancer in conjunction with a chemotherapeutic agent.SOLUTION: The inventors have discovered an agent that increases the expression of BAD, for use in the treatment of cancer in conjunction with a chemotherapeutic agent, wherein the agent is selected from the group consisting of 6-β-naltrexol, naloxone, methylnaltrexone, or pharmaceutically acceptable salts thereof.SELECTED DRAWING: Figure 1a

This invention relates to crystal- line salts of naloxone and of naltrexone and their use as opioid antagonists. The crystalline salts of the invention include naloxone saccharinate, nal- trexone succinate and a methanol solvate of nal- trexone succinate. A drug-in-adhesive trans- dermal patch containing the opioid analgesic fentanyl or an analog thereof and a crystalline salts of naloxone or naltrexone is disclosed. Also disclosed is a method of treating pain, such as acute, chronic or intermittent pain, by applying a drug-in-adhesive transdermal patch of the inven- tion to the skin of a patient in need thereof.

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

A method of producing promorphinan, morphinan, nal-opioid, and nor-opioid alkaloid products through the increased conversion of a promorphinan alkaloid to a morphinan alkaloid. The method comprises contacting the promorphinan alkaloid with at least one enzyme. Contacting the promorphinan alkaloid with the at least one enzyme converts the promorphinan alkaloid to a Morphinan alkaloid.

Aspects of the invention include topical naloxone compositions for topical delivery of naloxone to the skin of a subject. The topical composition according to certain embodiments is a storage stable non-aqueous topical composition comprising a naloxone free base and a non-aqueous solvent wherein the composition is substantially free of naloxone N-oxide. The invention also provides a method for locally delivering naloxone to a subject by using the external use composition, and a kit containing the external use naloxone composition.

To provide a method for producing an antibody or a functional fragment thereof that can specifically bind to naloxone and naltrexone.SOLUTION: The method comprises the steps of: immunizing a non-human animal with a conjugate comprising the structure of Formula III, thereby inducing B cells that produce an antibody binding to the conjugate (A is -O-, -N-, or -S-; B is -CO-, a lower alkyl, -CONH-, -SO2-, or the like; C is a carrier protein; and R2 is an allyl or cyclopropyl group); and obtaining an antibody or a functional fragment thereof produced by the B cells.SELECTED DRAWING: Figure 1

An overdose of opioids can cause the user to stop breathing, resulting in death. A physiological monitoring system monitors respiration based on oxygen saturation readings from a fingertip pulse oximeter in communication with a smart mobile device and sends opioid monitoring information from the smart mobile device to an opioid overdose monitoring service. The opioid overdose monitoring service notifies a first set of contacts when the opioid monitoring information indicates a non-distress stats and notifies a second set of contact when the opioid monitoring information indicates an overdose event. The notification can be a phone call or text message to a specified person, emergency personnel, or first responders, and can include the location of the smart mobile device. The smart mobile device can also include the location of the nearest treatment center having emergency medication used in treating opioid overdose, such as naloxone.

The invention discloses a morphone reductase mutant, and also discloses a polynucleotide related to the morphone reductase mutant, an expression vector, a host cell and a production method. The morphone reductase mutant provided by the invention or a cell for expressing the morphone reductase mutant can be used for converting 7, 8-didehydronaloxone into naloxone through a specific biological conversion reaction, so that not only is the effective removal of impurities realized, but also the yield of naloxone is increased.

A pharmaceutical composition in the form of droplets for oral administration is disclosed. The pharmaceutical composition is an aqueous solution comprising sodium chloride in an amount of 0.6% to 3% by weight per volume, at least one active ingredient selected from naloxone, yohimbine, albuterol, epinephrine, buprenorphine, and exosomes in an amount of 0.01% to 25% by weight per volume, and having a pH from 3 to 7.5. The composition is converted into droplets with diameters of 0.5 to 5 microns using an atomizer with a vibrating mesh membrane undergoing piezoelectric vibration at a frequency of 25 to 400 kilohertz. The process involves providing the composition in a capsule, inserting the capsule into the atomizer, and activating the atomizer to produce droplets. This system provides precise, efficient, and patient-friendly oral delivery of medications.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a morphine naloxone pharmaceutical composition and application thereof.The morphine naloxone pharmaceutical composition comprises morphine sulfate and naloxone hydrochloride as active ingredients, and the weight ratio of morphine sulfate to naloxone hydrochloride is 1: 1-6: 1; the invention also provides an application of the morphinaloxone pharmaceutical composition in preparation of a medicine for treating pain. The pharmaceutical composition is good in dissolution property and good in stability, and the technical problem of misuse of morphine sulfate can be avoided.